Adrian V S Hill

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7612716/publications.pdf

Version: 2024-02-01

		3515	3394
275	38,420	90	183
papers	citations	h-index	g-index

288	288	288	40168
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	6.3	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	6.3	2,080
3	Common West African HLA antigens are associated with protection from severe malaria. Nature, 1991, 352, 595-600.	13.7	1,494
4	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	6.3	1,196
5	Variation in the TNF-Î± promoter region associated with susceptibility to cerebral malaria. Nature, 1994, 371, 508-511.	13.7	1,169
6	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	6.3	979
7	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	15.2	900
8	Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Medicine, 1998, 4, 397-402.	15.2	640
9	Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature, 1992, 360, 434-439.	13.7	638
10	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	6.3	540
11	Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine, 2004, 10, 1240-1244.	15.2	538
12	Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Medicine, 2003, 9, 729-735.	15.2	536
13	Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respiratory Medicine,the, 2016, 4, 259-271.	5.2	536
14	In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nature Medicine, 2000, 6, 337-342.	15.2	521
15	THE IMMUNOGENETICS OF HUMAN INFECTIOUS DISEASES. Annual Review of Immunology, 1998, 16, 593-617.	9.5	513
16	Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet, The, 2001, 358, 1927-1934.	6.3	485
17	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	15.2	473
18	Bayesian refinement of association signals for 14 loci in 3 common diseases. Nature Genetics, 2012, 44, 1294-1301.	9.4	469

#	Article	IF	Citations
19	Genetics of susceptibitlity to human infectious disease. Nature Reviews Genetics, 2001, 2, 967-977.	7.7	447
20	Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. Clinical Infectious Diseases, 2011, 52, 1-7.	2.9	424
21	Human genetic susceptibility to infectious disease. Nature Reviews Genetics, 2012, 13, 175-188.	7.7	413
22	Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man. Science Translational Medicine, 2012, 4, 115ra1.	5.8	356
23	Vaccines against intracellular infections requiring cellular immunity. Nature, 2000, 406, 793-798.	13.7	334
24	Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. Nature Genetics, 2010, 42, 739-741.	9.4	332
25	Identifying Recent Adaptations in Large-Scale Genomic Data. Cell, 2013, 152, 703-713.	13.5	325
26	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nature Genetics, 2015, 47, 717-726.	9.4	310
27	A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLoS ONE, 2012, 7, e40385.	1.1	301
28	A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Science Translational Medicine, 2014, 6, 261ra153.	5.8	297
29	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. New England Journal of Medicine, 2016, 374, 1635-1646.	13.9	295
30	Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nature Genetics, 1997, 17, 11-12.	9.4	291
31	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	15.2	265
32	Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species. Science Translational Medicine, 2012, 4, 115ra2.	5.8	257
33	Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nature Communications, 2013, 4, 2836.	5.8	256
34	Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet, The, 2021, 397, 1809-1818.	6.3	253
35	Aspects of Genetic Susceptibility to Human Infectious Diseases. Annual Review of Genetics, 2006, 40, 469-486.	3.2	244
36	The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nature Communications, 2011, 2, 601.	5.8	233

#	Article	IF	Citations
37	Severe Malarial Anemia and Cerebral Malaria Are Associated with Different Tumor Necrosis Factor Promoter Alleles. Journal of Infectious Diseases, 1999, 179, 287-290.	1.9	231
38	Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4836-4841.	3.3	228
39	THEGENOMICS ANDGENETICS OFHUMANINFECTIOUSDISEASESUSCEPTIBILITY. Annual Review of Genomics and Human Genetics, 2001, 2, 373-400.	2.5	227
40	Preliminary Assessment of the Efficacy of a T-Cellâ€“Based Influenza Vaccine, MVA-NP+M1, in Humans. Clinical Infectious Diseases, 2012, 55, 19-25.	2.9	224
41	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	6.3	214
42	Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis. Infection and Immunity, 2001, 69, 681-686.	1.0	213
43	Glucose-6-phosphate dehydrogenase deficiency and malaria. Journal of Molecular Medicine, 1998, 76, 581-588.	1.7	210
44	ChAd63-MVAâ€“vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. Molecular Therapy, 2012, 20, 2355-2368.	3.7	196
45	Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. Journal of Infectious Diseases, 2012, 205, 772-781.	1.9	194
46	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485.	2.1	190
47	Viral vectors as vaccine platforms: deployment in sight. Current Opinion in Immunology, 2011, 23, 377-382.	2.4	188
48	Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. Molecular Therapy, 2014, 22, 464-475.	3.7	188
49	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2016, 16, 31-42.	4.6	187
50	Prime-boost vectored malaria vaccines: Progress and prospects. Hum Vaccin, 2010, 6, 78-83.	2.4	184
51	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infectious Diseases, The, 2020, 20, 816-826.	4.6	182
52	Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunological Reviews, 1999, 170, 29-38.	2.8	179
53	Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8 ⁺ T-Cell Responses. Infection and Immunity, 2010, 78, 145-153.	1.0	178
54	Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 328-339.	2.5	178

#	Article	IF	Citations
55	A major susceptibility locus for leprosy in India maps to chromosome 10p13. Nature Genetics, 2001, 27, 439-441.	9.4	171
56	Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respiratory Medicine,the, 2015, 3, 53-60.	5.2	166
57	Vaccines against malaria. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2806-2814.	1.8	165
58	Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens. Molecular Therapy, 2014, 22, 668-674.	3.7	165
59	Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Scientific Reports, 2017, 7, 46621.	1.6	158
60	Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. PLoS ONE, 2012, 7, e31208.	1.1	157
61	Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous primeâ€“boost immunisation regimes. Vaccine, 2002, 20, 1039-1045.	1.7	156
62	Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. Molecular Therapy, 2011, 19, 2269-2276.	3.7	156
63	Heterogeneity of Microsatellite Mutations Within and Between Loci, and Implications for Human Demographic Histories. Genetics, 1998, 148, 1269-1284.	1.2	154
64	A protein particle vaccine containing multiple malaria epitopes. Nature Biotechnology, 1997, 15, 1280-1284.	9.4	153
65	Calculation of Liverâ€toâ€Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites. Journal of Infectious Diseases, 2005, 191, 619-626.	1.9	152
66	Potent Induction of Focused Th1â€Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a RecombinantPlasmodium falciparumMalaria Vaccine. Journal of Infectious Diseases, 1999, 180, 1656-1664.	1.9	148
67	Effective induction of high-titer antibodies by viral vector vaccines. Nature Medicine, 2008, 14, 819-821.	15.2	148
68	Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers. Journal of Immunology, 2005, 174, 449-455.	0.4	143
69	Coated microneedle arrays for transcutaneous delivery of live virus vaccines. Journal of Controlled Release, 2012, 159, 34-42.	4.8	141
70	Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass. Science Translational Medicine, 2010, 2, 19ra12.	5.8	139
71	Innate Immune Responses to Human Malaria: Heterogeneous Cytokine Responses to Blood-Stage Plasmodium falciparum Correlate with Parasitological and Clinical Outcomes. Journal of Immunology, 2006, 177, 5736-5745.	0.4	138
72	Viral vectors as vaccine platforms: from immunogenicity to impact. Current Opinion in Immunology, 2016, 41, 47-54.	2.4	137

#	Article	IF	Citations
73	ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine, 2017, 35, 3780-3788.	1.7	133
74	Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology, 2005, 41, 1383-1390.	3.6	125
75	Pre-erythrocytic malaria vaccines: towards greater efficacy. Nature Reviews Immunology, 2006, 6, 21-32.	10.6	125
76	A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLOS Clinical Trials, 2006, 1, e29.	3.5	124
77	Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria. Journal of Immunology, 2005, 175, 5675-5680.	0.4	123
78	Genomic modulators of gene expression in human neutrophils. Nature Communications, 2015, 6, 7545.	5.8	120
79	Evolution, revolution and heresy in the genetics of infectious disease susceptibility. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 840-849.	1.8	117
80	Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania. Nature Communications, 2017, 8, 14946.	5.8	114
81	Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Science Translational Medicine, 2015, 7, 286re5.	5.8	113
82	CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria. Journal of Immunology, 2011, 187, 1347-1357.	0.4	110
83	Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. Journal of Infectious Diseases, 2015, 211, 1076-1086.	1.9	110
84	Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosisâ€“infected Individuals. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 724-733.	2.5	107
85	A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years. PLoS ONE, 2012, 7, e48322.	1.1	107
86	Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses. Molecular Therapy, 2014, 22, 233-238.	3.7	101
87	Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial. PLoS ONE, 2008, 3, e1493.	1.1	99
88	Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever. Scientific Reports, 2016, 6, 20617.	1.6	98
89	Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nature Medicine, 1999, 5, 565-571.	15.2	96
90	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01_BWith Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. Journal of Infectious Diseases, 2016, 214, 772-781.	1.9	96

#	Article	IF	Citations
91	QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION FOR MALARIA DIAGNOSIS AND ITS USE IN MALARIA VACCINE CLINICAL TRIALS. American Journal of Tropical Medicine and Hygiene, 2005, 73, 191-198.	0.6	96
92	Singleâ€dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. European Journal of Immunology, 2008, 38, 732-741.	1.6	95
93	Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Frontiers in Microbiology, 2014, 5, 686.	1.5	95
94	High frequencies of circulating IFN-Î³-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restrictedMycobacterium tuberculosis epitope inM. tuberculosis-infected subjects without disease. European Journal of Immunology, 2000, 30, 2713-2721.	1.6	94
95	Language continuity despite population replacement in Remote Oceania. Nature Ecology and Evolution, 2018, 2, 731-740.	3.4	91
96	Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. European Journal of Immunology, 1996, 26, 1951-1959.	1.6	89
97	Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance. Journal of Immunology, 2005, 175, 7264-7273.	0.4	89
98	The Induction and Persistence of T Cell IFN-Î³ Responses after Vaccination or Natural Exposure Is Suppressed byPlasmodium falciparum. Journal of Immunology, 2007, 179, 4193-4201.	0.4	88
99	Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA). PLoS ONE, 2008, 3, e1638.	1.1	87
100	A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine, 2006, 24, 2850-2859.	1.7	86
101	Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS ONE, 2011, 6, e22271.	1.1	84
102	Genetic susceptibility to invasive Salmonella disease. Nature Reviews Immunology, 2015, 15, 452-463.	10.6	81
103	Protection fromPlasmodium berghei infection by priming and boosting Tâ€‰cells to a single class I-restricted epitope with recombinant carriers suitable for human use. European Journal of Immunology, 1998, 28, 4345-4355.	1.6	80
104	Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe. PLoS ONE, 2013, 8, e65960.	1.1	80
105	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike proteinâ€“specific T _H 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	5.8	80
106	Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. JCI Insight, 2017, 2, .	2.3	78
107	Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines. Journal of Immunology, 2010, 185, 7583-7595.	0.4	76
108	Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?. Human Vaccines and Immunotherapeutics, 2012, 8, 706-714.	1.4	73

#	Article	IF	Citations
109	Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine, 2005, 23, 857-864.	1.7	72
110	Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. American Journal of Tropical Medicine and Hygiene, 2005, 73, 191-8.	0.6	71
111	Genetic analysis of hostâ€“parasite coevolution in human malaria. Philosophical Transactions of the Royal Society B: Biological Sciences, 1997, 352, 1317-1325.	1.8	70
112	Identification of Targets of CD8+ T Cell Responses to Malaria Liver Stages by Genome-wide Epitope Profiling. PLoS Pathogens, 2013, 9, e1003303.	2.1	70
113	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nature Communications, 2018, 9, 2441.	5.8	69
114	Identification of antigens presented by MHC for vaccines against tuberculosis. Npj Vaccines, 2020, 5, 2.	2.9	69
115	Microneedle Array Design Determines the Induction of Protective Memory CD8+ T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice. PLoS ONE, 2011, 6, e22442.	1.1	68
116	Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial. Molecular Therapy, 2014, 22, 2142-2154.	3.7	68
117	Prime and target immunization protects against liver-stage malaria in mice. Science Translational Medicine, 2018, 10, .	5.8	68
118	Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA primeâ€“boost immunisation in non-human primates. Vaccine, 2010, 29, 256-265.	1.7	67
119	Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Human Vaccines and Immunotherapeutics, 2017, 13, 3020-3032.	1.4	67
120	Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice. PLoS ONE, 2013, 8, e67888.	1.1	66
121	Genetic linkage of mild malaria to the major histocompatibility complex in Gambian children: study of affected sibling pairs. BMJ: British Medical Journal, 1997, 315, 96-97.	2.4	66
122	Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials. PLoS ONE, 2012, 7, e38434.	1.1	66
123	Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria. Cell Host and Microbe, 2009, 5, 95-105.	5.1	65
124	Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure. PLoS ONE, 2014, 9, e107903.	1.1	65
125	Native American gene flow into Polynesia predating Easter Island settlement. Nature, 2020, 583, 572-577.	13.7	64
126	Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. PLoS ONE, 2013, 8, e57726.	1.1	64

#	Article	IF	Citations
127	Association of hepatitis B surface antigen carriage with severe malaria in Gambian children. Nature Medicine, 1995, 1, 374-375.	15.2	62
128	Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein. Infection and Immunity, 2006, 74, 2706-2716.	1.0	62
129	Consanguinity and susceptibility to infectious diseases in humans. Biology Letters, 2009, 5, 574-576.	1.0	62
130	Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity. Journal of Immunology, 2005, 175, 599-606.	0.4	60
131	A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 290-295.	3.3	59
132	Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. Journal of Infectious Diseases, 2019, 219, 1187-1197.	1.9	59
133	Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLoS ONE, 2007, 2, e707.	1.1	57
134	The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus. Journal of Immunology, 2011, 187, 2602-2616.	0.4	55
135	Cytotoxic T lymphocytes toPlasmodium falciparum epitopes in an area of intense and perennial transmission in Tanzania. European Journal of Immunology, 1996, 26, 773-779.	1.6	54
136	PTPN22 and invasive bacterial disease. Nature Genetics, 2006, 38, 499-500.	9.4	54
137	Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials. Vaccines, 2018, 6, 50.	2.1	54
138	The Immunogenetics of Resistance to Malaria. Proceedings of the Association of American Physicians, 1999, 111, 272-277.	2.1	54
139	Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection. Journal of Infectious Diseases, 2013, 208, 340-345.	1.9	53
140	Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites. Infection and Immunity, 2014, 82, 1277-1286.	1.0	53
141	Progress with viral vectored malaria vaccines: A multi-stage approach involving â€œunnatural immunityâ€• Vaccine, 2015, 33, 7444-7451.	1.7	53
142	First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. PLoS ONE, 2018, 13, e0208328.	1.1	53
143	Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Molecular Therapy, 2016, 24, 1470-1477.	3.7	52
144	Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice. Virology Journal, 2013, 10, 349.	1.4	51

#	Article	IF	Citations
145	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. Npj Vaccines, 2018, 3, 49.	2.9	51
146	Direct processing and presentation of antigen from malaria sporozoites by professional antigenâ€presenting cells in the induction of CD8 + Tâ€cell responses. Immunology and Cell Biology, 2005, 83, 307-312.	1.0	49
147	Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations. Molecular Therapy, 2014, 22, 1992-2003.	3.7	49
148	Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Scientific Reports, 2015, 5, 11820.	1.6	49
149	A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS. PLoS ONE, 2014, 9, e115161.	1.1	48
150	Estimating the burden of iron deficiency among African children. BMC Medicine, 2020, 18, 31.	2.3	47
151	A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine, 2011, 29, 7514-7522.	1.7	46
152	Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. Scientific Reports, 2014, 4, 6154.	1.6	46
153	Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. PLoS ONE, 2016, 11, e0167951.	1.1	46
154	Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis. Science Advances, 2017, 3, e1602096.	4.7	46
155	Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1. PLoS ONE, 2011, 6, e20977.	1.1	45
156	Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa. PLoS ONE, 2008, 3, e2921.	1.1	45
157	Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. European Journal of Immunology, 1995, 25, 1783-1787.	1.6	44
158	Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. Biotechnology and Bioengineering, 2012, 109, 719-728.	1.7	44
159	Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge. Infection and Immunity, 2007, 75, 5819-5826.	1.0	43
160	Fusion of the Mycobacterium tuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates. PLoS ONE, 2012, 7, e33555.	1.1	43
161	Analysis of human <scp>B</scp>â€cell responses following <scp>C</scp>h<scp>A</scp>d63â€<scp>MVA MSP</scp>1 and <scp>AMA</scp>1 immunization and controlled malaria infection. Immunology, 2014, 141, 628-644.	2.0	43
162	Chronic hepatitis C viral infection subverts vaccineâ€induced Tâ€cell immunity in humans. Hepatology, 2016, 63, 1455-1470.	3.6	43

#	Article	IF	Citations
163	TMEM203 is a binding partner and regulator of STING-mediated inflammatory signaling in macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16479-16488.	3.3	43
164	Combining Liver- and Blood-Stage Malaria Viral-Vectored Vaccines: Investigating Mechanisms of CD8+ T Cell Interference. Journal of Immunology, 2011, 187, 3738-3750.	0.4	41
165	Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models. Scientific Reports, 2017, 7, 46482.	1.6	41
166	Cryopreservation-related loss of antigen-specific IFNÎ³ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy. Vaccine, 2017, 35, 1898-1906.	1.7	40
167	A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. PLoS Neglected Tropical Diseases, 2018, 12, e0006870.	1.3	40
168	Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. Malaria Journal, 2015, 14, 33.	0.8	39
169	Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children. American Journal of Human Genetics, 2016, 98, 1092-1100.	2.6	39
170	Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors. Infection and Immunity, 2018, 86, .	1.0	39
171	Defence by diversity. Nature, 1999, 398, 668-669.	13.7	38
172	RNA and Imidazoquinolines Are Sensed by Distinct TLR7/8 Ectodomain Sites Resulting in Functionally Disparate Signaling Events. Journal of Immunology, 2014, 192, 5963-5973.	0.4	38
173	Searching for the human genetic factors standing in the way of universally effective vaccines. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140341.	1.8	38
174	Iron Status and Associated Malaria Risk Among African Children. Clinical Infectious Diseases, 2019, 68, 1807-1814.	2.9	38
175	Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity. Molecular Therapy, 2012, 20, 1633-1647.	3.7	37
176	The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment. Scientific Reports, 2013, 3, 1706.	1.6	36
177	Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. Scientific Reports, 2015, 5, 16756.	1.6	36
178	Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. Vaccines, 2016, 4, 27.	2.1	35
179	Malaria is a cause of iron deficiency in African children. Nature Medicine, 2021, 27, 653-658.	15.2	35
180	HIV and HLA: Confusion or complexity?. Nature Medicine, 1996, 2, 395-396.	15.2	34

#	Article	IF	Citations
181	Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. Molecular Therapy, 2017, 25, 547-559.	3.7	34
182	Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Scientific Reports, 2018, 8, 3390.	1.6	34
183	Targeting Antigen to the Surface of EVs Improves the InÂVivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice. Molecular Therapy - Methods and Clinical Development, 2020, 16, 108-125.	1.8	34
184	EX VIVO INTERFERON-GAMMA IMMUNE RESPONSE TO THROMBOSPONDIN-RELATED ADHESIVE PROTEIN IN COASTAL KENYANS: LONGEVITY AND RISK OF PLASMODIUM FALCIPARUM INFECTION. American Journal of Tropical Medicine and Hygiene, 2003, 68, 421-430.	0.6	34
185	Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain. PLoS ONE, 2014, 9, e100538.	1.1	33
186	Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats. Npj Vaccines, 2019, 4, 44.	2.9	31
187	Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. Journal of Experimental Medicine, 2020, 217, .	4.2	31
188	A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nature Communications, 2021, 12, 4636.	5.8	31
189	Paths and timings of the peopling of Polynesia inferred from genomic networks. Nature, 2021, 597, 522-526.	13.7	31
190	Induction of CD8+ T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. Vaccine, 2015, 33, 3248-3255.	1.7	30
191	Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens. Journal of Immunology, 2018, 201, 1315-1326.	0.4	30
192	Recombinant Viral-Vectored Vaccines ExpressingPlasmodium chabaudiAS Apical Membrane Antigen 1: Mechanisms of Vaccine-Induced Blood-Stage Protection. Journal of Immunology, 2012, 188, 5041-5053.	0.4	29
193	Risk of nontyphoidal Salmonella bacteraemia in African children is modified by STAT4. Nature Communications, 2018, 9, 1014.	5.8	29
194	Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle. Vaccine, 2016, 34, 2296-2298.	1.7	28
195	External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance. PLoS ONE, 2014, 9, e97398.	1.1	28
196	Identification of hostâ€“pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank. Nature Communications, 2022, 13, 1818.	5.8	28
197	A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes. Journal of Experimental Medicine, 2022, 219, .	4.2	28
198	Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-Mâ„¢. Vaccine, 2017, 35, 6208-6217.	1.7	27

#	Article	IF	Citations
199	A P. falciparum NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages. Frontiers in Cellular and Infection Microbiology, 2019, 9, 96.	1.8	27
200	Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. , 2020, 8, e000928.		27
201	CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria. Frontiers in Immunology, 2018, 9, 1660.	2.2	26
202	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, .	2.3	26
203	Vaccines and global health. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2733-2742.	1.8	25
204	Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. Journal of Medical Virology, 2001, 65, 664-670.	2.5	24
205	Variants in the Mannose-binding Lectin GeneMBL2do not Associate With Sepsis Susceptibility or Survival in a Large European Cohort. Clinical Infectious Diseases, 2015, 61, 695-703.	2.9	24
206	Improved method for distinguishing the human source of mosquito blood meals between close family members. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 572-574.	0.7	23
207	An integrated expression phenotype mapping approach defines common variants in LEP, ALOX15 and CAPNS1 associated with induction of IL-6. Human Molecular Genetics, 2010, 19, 720-730.	1.4	23
208	T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein. PLoS ONE, 2012, 7, e44943.	1.1	23
209	Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection. Journal of Immunology, 2013, 190, 1135-1147.	0.4	23
210	Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial. Frontiers in Immunology, 2017, 8, 1551.	2.2	23
211	Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. Vaccines, 2019, 7, 33.	2.1	23
212	Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection. PLoS ONE, 2012, 7, e50447.	1.1	23
213	Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. American Journal of Tropical Medicine and Hygiene, 2003, 68, 421-30.	0.6	23
214	Induction of CD8 + Tâ€lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus. Immunology and Cell Biology, 2001, 79, 569-575.	1.0	21
215	Malaria vaccines: identifying Plasmodium falciparum liver-stage targets. Frontiers in Microbiology, 2015, 6, 965.	1.5	21
216	Profiling the host response to malaria vaccination and malaria challenge. Vaccine, 2015, 33, 5316-5320.	1.7	21

#	Article	IF	Citations
217	The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. Vaccine, 2015, 33, 1121-1128.	1.7	20
218	Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine. Vaccine Journal, 2017, 24, .	3.2	20
219	The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia. Science Advances, 2019, 5, eaaw0109.	4.7	20
220	Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. Vaccine, 2009, 27, 5589-5598.	1.7	19
221	Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. Vaccines, 2019, 7, 40.	2.1	19
222	Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses. Scientific Reports, 2018, 8, 15020.	1.6	18
223	Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii. PLoS ONE, 2019, 14, e0210407.	1.1	18
224	The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8+ T Cells Present in the Liver. Journal of Immunology, 2017, 198, 2006-2016.	0.4	17
225	Development of an In Vitro Assay and Demonstration of Plasmodium berghei Liver-Stage Inhibition by TRAP-Specific CD8+ T Cells. PLoS ONE, 2015, 10, e0119880.	1.1	17
226	Maintenance of MHC polymorphism. Nature, 1992, 355, 403-403.	13.7	15
227	A distinctive peptide binding motif for HLA-DRB1 * 0407, an HLA-DR4 subtype not associated with rheumatoid arthritis. Immunogenetics, 1997, 45, 229-232.	1.2	15
228	Workshop report: Malaria vaccine development in Europeâ€“preparing for the future. Vaccine, 2015, 33, 6137-6144.	1.7	15
229	An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens. Scientific Reports, 2017, 7, 17011.	1.6	15
230	Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. Scientific Reports, 2018, 8, 3896.	1.6	15
231	Vaccine innovations for emerging infectious diseasesâ€”a symposium report. Annals of the New York Academy of Sciences, 2020, 1462, 14-26.	1.8	15
232	Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Control of Strong and Constitutive Promoters. Frontiers in Cellular and Infection Microbiology, 2020, 10, 270.	1.8	14
233	A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. Molecular Therapy, 2022, 30, 2024-2047.	3.7	14
234	Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. Vaccine, 2016, 34, 49-55.	1.7	13

#	Article	IF	Citations
235	Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria. Scientific Reports, 2017, 7, 7284.	1.6	13
236	Immunological considerations for SARS-CoV-2 human challenge studies. Nature Reviews Immunology, 2020, 20, 715-716.	10.6	13
237	Ancient DNA reveals five streams of migration into Micronesia and matrilocality in early Pacific seafarers. Science, 2022, 377, 72-79.	6.0	13
238	Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors. Vaccine Journal, 2014, 21, 901-903.	3.2	12
239	Genetic variation in VAC14 is associated with bacteremia secondary to diverse pathogens in African children. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3601-E3603.	3.3	12
240	Distinguishing malaria and influenza: Early clinical features in controlled human experimental infection studies. Travel Medicine and Infectious Disease, 2012, 10, 192-196.	1.5	10
241	Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice. Scientific Reports, 2021, 11, 10792.	1.6	10
242	Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. , 2021, 9, e003218.		10
243	Identification of 34 Novel Proinflammatory Proteins in a Genome-Wide Macrophage Functional Screen. PLoS ONE, 2012, 7, e42388.	1.1	9
244	The Human Leukocyte Antigen Locus and Rheumatic Heart Disease Susceptibility in South Asians and Europeans. Scientific Reports, 2020, 10, 9004.	1.6	9
245	Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule. Scientific Reports, 2020, 10, 5716.	1.6	9
246	Rare Variants in MYD88, IRAK4 and IKBKG and Susceptibility to Invasive Pneumococcal Disease: A Population-Based Case-Control Study. PLoS ONE, 2015, 10, e0123532.	1.1	8
247	4-1BBL Enhances CD8+ T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques. PLoS ONE, 2014, 9, e105520.	1.1	7
248	Towards a multi-antigen multi-stage malaria vaccine. Malaria Journal, 2014, 13, .	0.8	7
249	DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. Diseases (Basel, Switzerland), 2018, 6, 107.	1.0	7
250	Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria. Infection and Immunity, 2020, 88, .	1.0	7
251	Low immunogenicity of malaria preâ€erythrocytic stages can be overcome by vaccination. EMBO Molecular Medicine, 2021, 13, e13390.	3.3	7
252	Imputation Performance in Latin American Populations: Improving Rare Variants Representation With the Inclusion of Native American Genomes. Frontiers in Genetics, 2021, 12, 719791.	1.1	7

#	Article	IF	Citations
253	Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P.Âfalciparum Transmission-Blocking Candidate Pfs25 in Humans. Frontiers in Immunology, 2021, 12, 732667.	2.2	6
254	Protection from Plasmodium berghei infection by priming and boosting Tâ€‰cells to a single class I-restricted epitope with recombinant carriers suitable for human use. , 1998, 28, 4345.		6
255	Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria. Frontiers in Immunology, 2022, 13, 795463.	2.2	6
256	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. JCI Insight, 2022, 7, .	2.3	6
257	T-cell receptor variable alpha (TCRAV) polymorphisms in European, Chinese, South American, AfroCaribbean, and Gambian populations. Immunogenetics, 1997, 47, 124-130.	1.2	5
258	Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice. PLoS ONE, 2015, 10, e0144515.	1.1	5
259	Modeling Combinations of Pre-erythrocytic Plasmodium falciparum Malaria Vaccines. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1254-1259.	0.6	5
260	Elevated risk of invasive group A streptococcal disease and host genetic variation in the human leucocyte antigen locus. Genes and Immunity, 2020, 21, 63-70.	2.2	5
261	Risk of pneumococcal bacteremia in Kenyan children with glucose-6-phosphate dehydrogenase deficiency. BMC Medicine, 2020, 18, 148.	2.3	4
262	Quantitative Association Tests of Immune Responses to Antigens ofMycobacterium Tuberculosis: A Study of Twins in West Africa. Twin Research and Human Genetics, 2004, 7, 578-588.	1.5	3
263	Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies. Vaccines, 2021, 9, 262.	2.1	3
264	Dissection-independent production ofPlasmodiumsporozoites from whole mosquitoes. Life Science Alliance, 2021, 4, e202101094.	1.3	2
265	Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites. PLoS ONE, 2021, 16, e0254498.	1.1	2
266	Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation. Scientific Reports, 2021, 11, 20877.	1.6	2
267	Genetic susceptibility to multifactorial diseases. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 369-371.	0.7	1
268	COVIDâ€19 vaccines for rapid global impact. BJU International, 2021, 127, 137-139.	1.3	1
269	Human genetic susceptibility to infectious disease. , 0, .		1
270	Production of a high purity, Câ€tagged Hepatitis B surface Antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions. Biotechnology and Bioengineering, 0, , .	1.7	1

#	Article	IF	Citations
271	Clinical Evaluation of New Immunisation Strategies for Enhancing T Cell Responses against M. Tuberculosis. Clinical Science, 2003, 104, 51P-51P.	0.0	0
272	Identification of Susceptibility Genes for Tuberculosis in Southern and West Africans Using Family-Based Linkage Analysis and Linkage Disequilibrium Mapping. Clinical Science, 2003, 104, 56P-56P.	0.0	0
273	Jenner reborn: a new vaccine institute. Lancet, The, 2009, 373, 445-446.	6.3	0
274	Virus-like particle vaccines. , 2022, , 163-176.		0
275	New Malaria Vaccines: The DNA-MVA Prime-Boost Strategy. , 0, , 87-96.		0